Investor Presentaiton

sanofi Sanofi drives innovation with BiC/FIC vaccines pipeline. New products approved since Vaccines Investor Event in December 2021 3 mRNA 6 Leading-edge mRNA platform to lift our influenza standard of care and deliver innovation to address unmet needs At least 5 New vaccine candidates expected in phase 1/2 trial in 2022/23 First-in-Class / Best-in-Class vaccine candidates expected in phase 3 by 2025 across diverse preventative and therapeutic areas 112 Vaccines Investor Event

View entire presentation